Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Myriad Genetics (MYGN) over the last 9 years, with Q3 2025 value amounting to $0.32.

  • Myriad Genetics' Debt to Equity rose 50139.59% to $0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 50139.59%. This contributed to the annual value of $0.06 for FY2024, which is 1490.19% up from last year.
  • Myriad Genetics' Debt to Equity amounted to $0.32 in Q3 2025, which was up 50139.59% from $0.15 recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Debt to Equity peaked at $0.32 during Q3 2025, and registered a low of $0.05 during Q4 2023.
  • Moreover, its 4-year median value for Debt to Equity was $0.06 (2023), whereas its average is $0.09.
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 331648.18% in 2021, then tumbled by 538.81% in 2024.
  • Myriad Genetics' Debt to Equity (Quarter) stood at $0.12 in 2021, then crashed by 57.38% to $0.05 in 2023, then increased by 14.9% to $0.06 in 2024, then soared by 467.51% to $0.32 in 2025.
  • Its Debt to Equity stands at $0.32 for Q3 2025, versus $0.15 for Q2 2025 and $0.08 for Q1 2025.